Near-Infrared Spectroscopy Measurements in Chronic Obstructive Pulmonary Disease
Launched by TOKAT GAZIOSMANPASA UNIVERSITY · May 15, 2025
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study was a prospective observational analysis involving patients with diagnosed Chronic Obstructive Pulmonary Disease (COPD) and Chronic Kidney Disease (CKD). Participants were recruited from the pulmonary and nephrology clinics at Gaziosmanpasa University Health Application and Research Centre during their stay in the ward. The study was approved by the Tokat Gaziosmanpasa Research Ethics Committee (Grant number: 20-KAEK-212) and all patients provided informed consent prior to participation.
Data collection involved baseline assessments of demographic characteristics, COPD severity,...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * To be eligible for the study, patients were required to meet all of the following criteria:
- • 1. Age: Patients aged between 18 and 80 years.
- 2. COPD Diagnosis: A confirmed diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, including:
- • A post-bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio of \<0.70.
- 3. Renal Failure: Evidence of CKD, defined as:
- • An estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73 m² (Stages 3-5 CKD) on at least two occasions three months apart, or a history of renal replacement therapy.
- • 4. Stable Medical Condition: Clinically stable COPD, with no exacerbations or hospital admissions within the preceding four weeks.
- Exclusion Criteria:
- * Patients were excluded from the study if they met any of the following criteria:
- • 1. Acute Exacerbation: Evidence of an acute COPD exacerbation within four weeks prior to enrolment.
- • 2. Other Respiratory Disorders: Coexistence of other chronic respiratory diseases such as asthma, interstitial lung disease, or bronchiectasis that might interfere with the assessment of COPD.
- • 3. Renal Transplantation: History of kidney transplantation, as immunosuppressive therapy may affect disease progression and outcomes.
- 4. Uncontrolled Comorbidities: Presence of any uncontrolled comorbid conditions, including:
- • Cardiovascular instability or recent myocardial infarction (within six months).
- • Active malignancy (other than localized skin cancer).
- • Severe liver disease (e.g., cirrhosis with hepatic failure).
- • 5. Pregnancy or Breastfeeding: Women who were pregnant or breastfeeding at the time of study enrolment.
- • 6. Cognitive Impairment: Any condition that would impair the ability to provide informed consent or participate in study procedures, such as dementia or significant psychiatric disorders.
About Tokat Gaziosmanpasa University
Tokat Gaziosmanpasa University is a distinguished academic institution dedicated to advancing medical research and innovation through rigorous clinical trials. With a commitment to enhancing healthcare outcomes, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct comprehensive studies that address critical health challenges. By fostering collaboration among researchers, healthcare professionals, and industry partners, Tokat Gaziosmanpasa University aims to contribute valuable insights to the scientific community and improve patient care through evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokat, Center, Turkey
Patients applied
Trial Officials
Daniel MARTIN, Professor
Principal Investigator
Uni of Plymouth, Dept of Periop and ICU, Plymouth, UK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported